Studies acoramidis tablets in adults with transthyretin amyloid heart disease
Tests acoramidis tablets in adults with heart disease caused by transthyretin amyloidosis.
Plain-language title generated from the registry record
Registry title: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Key facts
- Where
- Aarhus N, DenmarkSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07695701, who can take part
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eidos Therapeutics, a BridgeBio company
- Trial code
- NCT07695701EU 2026-526068-19-00
- Record updated
- 29 July 2026
- Original description
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.Read full original descriptionShow less
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Inclusion: Participants aged 18 to 80; Confirmed diagnosis of ATTR-CM requiring targeted therapy; At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >35%; left ventricular (LV) wall thickness ≥12 mm; Heart failure condition has been clinically stable for at least 6 weeks prior to screening.
Exclusion: Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening; Prior or current treatment with acoramidis; Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator); Likely to undergo heart transplantation within 12 months from screening; Hemodynamic instability; Confirmed diagnosis of AL amyloidosis at screening; At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.